QQQ   416.58 (-1.61%)
AAPL   165.21 (-1.10%)
MSFT   400.47 (-0.94%)
META   482.95 (-3.76%)
GOOGL   153.94 (-1.33%)
AMZN   174.91 (-2.40%)
TSLA   147.99 (-1.29%)
NVDA   787.22 (-7.03%)
AMD   147.62 (-4.81%)
NIO   3.83 (-4.25%)
BABA   68.99 (+0.16%)
T   16.47 (+0.86%)
F   12.11 (+0.41%)
MU   107.10 (-4.32%)
GE   148.90 (-2.64%)
CGC   8.05 (+2.81%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.12 (+0.03%)
XOM   120.00 (+1.25%)
QQQ   416.58 (-1.61%)
AAPL   165.21 (-1.10%)
MSFT   400.47 (-0.94%)
META   482.95 (-3.76%)
GOOGL   153.94 (-1.33%)
AMZN   174.91 (-2.40%)
TSLA   147.99 (-1.29%)
NVDA   787.22 (-7.03%)
AMD   147.62 (-4.81%)
NIO   3.83 (-4.25%)
BABA   68.99 (+0.16%)
T   16.47 (+0.86%)
F   12.11 (+0.41%)
MU   107.10 (-4.32%)
GE   148.90 (-2.64%)
CGC   8.05 (+2.81%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.12 (+0.03%)
XOM   120.00 (+1.25%)
QQQ   416.58 (-1.61%)
AAPL   165.21 (-1.10%)
MSFT   400.47 (-0.94%)
META   482.95 (-3.76%)
GOOGL   153.94 (-1.33%)
AMZN   174.91 (-2.40%)
TSLA   147.99 (-1.29%)
NVDA   787.22 (-7.03%)
AMD   147.62 (-4.81%)
NIO   3.83 (-4.25%)
BABA   68.99 (+0.16%)
T   16.47 (+0.86%)
F   12.11 (+0.41%)
MU   107.10 (-4.32%)
GE   148.90 (-2.64%)
CGC   8.05 (+2.81%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.12 (+0.03%)
XOM   120.00 (+1.25%)
QQQ   416.58 (-1.61%)
AAPL   165.21 (-1.10%)
MSFT   400.47 (-0.94%)
META   482.95 (-3.76%)
GOOGL   153.94 (-1.33%)
AMZN   174.91 (-2.40%)
TSLA   147.99 (-1.29%)
NVDA   787.22 (-7.03%)
AMD   147.62 (-4.81%)
NIO   3.83 (-4.25%)
BABA   68.99 (+0.16%)
T   16.47 (+0.86%)
F   12.11 (+0.41%)
MU   107.10 (-4.32%)
GE   148.90 (-2.64%)
CGC   8.05 (+2.81%)
DIS   112.39 (-0.04%)
AMC   3.18 (+8.90%)
PFE   25.88 (+1.93%)
PYPL   62.12 (+0.03%)
XOM   120.00 (+1.25%)
Free Trial

Ligand Pharmaceuticals (LGND) Earnings Date, Estimates & Call Transcripts

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)
Free lgnd Stock Alerts
$72.21
-0.31 (-0.43%)
(As of 02:26 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 2Estimated
Actual EPS
(Feb. 27)
$0.79 Beat By $0.55
Consensus EPS
(Feb. 27)
$0.24
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

LGND Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LGND Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Ligand Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20241$0.75$0.75$0.75 
Q2 20241$0.67$0.67$0.67 
Q3 20241$0.80$0.80$0.80 
Q4 20241$0.75$0.75$0.75 
FY 20244$2.97$2.97$2.97 
Q1 20251$0.98$0.98$0.98 
Q2 20251$1.01$1.01$1.01 
Q3 20251$1.00$1.00$1.00 
20253$2.99$2.99$2.99 
Q1 20261$1.19$1.19$1.19 

LGND Earnings Date and Information

Ligand Pharmaceuticals last posted its quarterly earnings data on February 27th, 2024. The biotechnology company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.55. The company earned $28.10 million during the quarter, compared to the consensus estimate of $24.54 million. Ligand Pharmaceuticals has generated $2.75 earnings per share over the last year ($2.75 diluted earnings per share) and currently has a price-to-earnings ratio of 26.3. Earnings for Ligand Pharmaceuticals are expected to grow by 16.72% in the coming year, from $3.41 to $3.98 per share. Ligand Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off prior year's report dates.

Ligand Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Estimated)		------- 
2/27/2024Q4 2023$0.24$0.79+$0.55$0.55$24.54 million$28.10 million
11/8/2023Q3 2023$0.68$1.02+$0.34$2.16$27.22 million$32.87 million    
8/8/2023Q2 2023$0.76$1.42+$0.66$2.07$24.74 million$26.37 million    
5/4/2023Q1 2023$0.89$2.28+$1.39$1.59$33.55 million$43.98 million    
2/22/2023Q4 2022$1.23$1.36+$0.13$0.52$39.63 million$50.40 million    
11/7/2022Q3 2022$0.09($0.20)($0.29)($0.42)$38.47 million$66.09 million
8/8/2022Q2 2022$0.12($0.14)($0.26)($0.23)$39.70 million$57.42 million
5/4/2022Q1 2022$0.19$0.15($0.04)$1.21$34.21 million$45.70 million      
2/17/2022Q4 2021$0.97$1.34+$0.37$2.98$62.70 million$72.47 million    
11/9/2021Q3 2021$0.61$1.58+$0.97$1.56$60.46 million$64.84 million    
7/29/2021Q2 2021$1.15$1.63+$0.48$0.53$73.32 million$84.68 million    
5/2/2021Q1 2021$1.13$1.41+$0.28$1.01$63.00 million$55.10 million  

Ligand Pharmaceuticals Earnings - Frequently Asked Questions

When is Ligand Pharmaceuticals's earnings date?

Ligand Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 2nd, 2024 based off last year's report dates. Learn more on LGND's earnings history.

Did Ligand Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Ligand Pharmaceuticals (NASDAQ:LGND) reported $0.79 earnings per share (EPS) to beat the analysts' consensus estimate of $0.24 by $0.55. Learn more on analysts' earnings estimate vs. LGND's actual earnings.

How much revenue does Ligand Pharmaceuticals generate each year?

Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded annual revenue of $131.31 million.

How much profit does Ligand Pharmaceuticals generate each year?

Ligand Pharmaceuticals (NASDAQ:LGND) has a recorded net income of $52.15 million. LGND has generated $2.75 earnings per share over the last four quarters.

What is Ligand Pharmaceuticals's price-to-earnings ratio?

Ligand Pharmaceuticals (NASDAQ:LGND) has a trailing price-to-earnings ratio of 26.35 and a forward price-to-earnings ratio of 21.25.

What is Ligand Pharmaceuticals's EPS forecast for next year?

Ligand Pharmaceuticals's earnings are expected to grow from $3.41 per share to $3.98 per share in the next year, which is a 16.72% increase.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:LGND) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
The “Perfect Storm” for Gold
Gold Safe Exchange
Strange new buyer driving up gold
Stansberry Research
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
SHOCKING Crypto Leak…
Crypto 101 Media
Top 5 AI Stocks to Buy for 2024
Market Moving Trends